BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 20542069)

  • 1. The broad-spectrum antitumor action of cyclosporin A is due to its tachykinin receptor antagonist pharmacological profile.
    Muñoz M; Rosso M; González A; Saenz J; Coveñas R
    Peptides; 2010 Sep; 31(9):1643-8. PubMed ID: 20542069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The NK-1 receptor is expressed in human primary gastric and colon adenocarcinomas and is involved in the antitumor action of L-733,060 and the mitogenic action of substance P on human gastrointestinal cancer cell lines.
    Rosso M; Robles-Frías MJ; Coveñas R; Salinas-Martín MV; Muñoz M
    Tumour Biol; 2008; 29(4):245-54. PubMed ID: 18781096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumoral action of the neurokinin-1-receptor antagonist L-733,060 and mitogenic action of substance P on human retinoblastoma cell lines.
    Muñoz M; Rosso M; Pérez A; Coveñas R; Rosso R; Zamarriego C; Soult JA; Montero I
    Invest Ophthalmol Vis Sci; 2005 Jul; 46(7):2567-70. PubMed ID: 15980249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurokinin-1 receptors located in human retinoblastoma cell lines: antitumor action of its antagonist, L-732,138.
    Muñoz M; Rosso M; Coveñas R; Montero I; González-Moles MA; Robles MJ
    Invest Ophthalmol Vis Sci; 2007 Jun; 48(6):2775-81. PubMed ID: 17525212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The substance P/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists.
    Muñoz M; González-Ortega A; Rosso M; Robles-Frias MJ; Carranza A; Salinas-Martín MV; Coveñas R
    Peptides; 2012 Dec; 38(2):318-25. PubMed ID: 23026680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uveal melanoma expresses NK-1 receptors and cyclosporin A induces apoptosis in human melanoma cell lines overexpressing the NK-1 receptor.
    González-Ortega A; Sánchez-Vaderrábanos E; Ramiro-Fuentes S; Salinas-Martín MV; Carranza A; Coveñas R; Muñoz M
    Peptides; 2014 May; 55():1-12. PubMed ID: 24548567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The NK1 receptor is involved in the antitumoural action of L-733,060 and in the mitogenic action of substance P on neuroblastoma and glioma cell lines.
    Muñoz M; Rosso M; Pérez A; Coveñas R; Rosso R; Zamarriego C; Piruat JI
    Neuropeptides; 2005 Aug; 39(4):427-32. PubMed ID: 15939468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumoural action of L-733,060 on neuroblastoma and glioma cell lines.
    Muñoz M; Pérez A; Coveñas R; Rosso M; Castro E
    Arch Ital Biol; 2004 Mar; 142(2):105-12. PubMed ID: 15248566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NK-1 receptor antagonists induce apoptosis and counteract substance P-related mitogenesis in human laryngeal cancer cell line HEp-2.
    Muñoz M; Rosso M; Aguilar FJ; González-Moles MA; Redondo M; Esteban F
    Invest New Drugs; 2008 Apr; 26(2):111-8. PubMed ID: 17906845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The antiproliferative action of [D-Arg(1), D-Phe(5), D-Trp(7,9), LEU(11)] substance P analogue antagonist against small-cell- and non-small-cell lung cancer cells could be due to the pharmacological profile of its tachykinin receptor antagonist.
    Munoz M; Recio S; Rosso M; Redondo M; Covenas R
    J Physiol Pharmacol; 2015 Jun; 66(3):421-6. PubMed ID: 26084224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug.
    Muñoz M; Rosso M
    Invest New Drugs; 2010 Apr; 28(2):187-93. PubMed ID: 19148578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NK-1 receptor antagonists as antitumor drugs: a survey of the literature from 2000 to 2011.
    Muñoz M; Martinez-Armesto J; Coveñas R
    Expert Opin Ther Pat; 2012 Jul; 22(7):735-46. PubMed ID: 22697287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacology of MEN 11467: a potent new selective and orally- effective peptidomimetic tachykinin NK(1) receptor antagonist.
    Cirillo R; Astolfi M; Conte B; Lopez G; Parlani M; Sacco G; Terracciano R; Fincham CI; Sisto A; Evangelista S; Maggi CA; Manzini S
    Neuropeptides; 2001; 35(3-4):137-47. PubMed ID: 11884203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurokinin-1 receptor: a new promising target in the treatment of cancer.
    Muñoz M; Coveñas R
    Discov Med; 2010 Oct; 10(53):305-13. PubMed ID: 21034671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tachykinin activation of human monocytes from patients with rheumatoid arthritis: in vitro and ex-vivo effects of cyclosporin A.
    Lavagno L; Bordin G; Colangelo D; Viano I; Brunelleschi S
    Neuropeptides; 2001 Apr; 35(2):92-9. PubMed ID: 11384204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclosporine a induces growth arrest or programmed cell death of human glioma cells.
    Zupanska A; Dziembowska M; Ellert-Miklaszewska A; Gaweda-Walerych K; Kaminska B
    Neurochem Int; 2005 Nov; 47(6):430-41. PubMed ID: 16087277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of cyclosporin on cell division and apoptosis in human oral keratinocytes.
    Birraux J; Kirby JA; Thomason JM; Taylor JJ
    J Periodontal Res; 2006 Aug; 41(4):297-302. PubMed ID: 16827723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological examination of the neurokinin-1 receptor mediating relaxation of human intralobar pulmonary artery.
    Pedersen KE; Buckner CK; Meeker SN; Undem BJ
    J Pharmacol Exp Ther; 2000 Jan; 292(1):319-25. PubMed ID: 10604965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines.
    Muñoz M; Rosso M; Robles-Frias MJ; Salinas-Martín MV; Rosso R; González-Ortega A; Coveñas R
    Lab Invest; 2010 Aug; 90(8):1259-69. PubMed ID: 20458280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.